

monitoring the administration of psychotropic medication to children in ORR custody and care.

Samantha L. Illangasekare,
ACF/OPRE Certifying Officer.

[FR Doc. 2026–20314 Filed 10–2–26; 8:45 am]

BILLING CODE 4184–45–P

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Advisory Council on Alzheimer's Research, Care, and Services; Meeting

AGENCY: Assistant Secretary for Planning and Evaluation, HHS.

ACTION: Notice of meeting.

SUMMARY: This notice announces the public meeting of the Advisory Council on Alzheimer's Research, Care, and Services (Advisory Council) and the U.S. Department of Health and Human Services Alzheimer's Disease and Related Dementias Summit. The Advisory Council provides advice on how to prevent or reduce the burden of Alzheimer's disease and related dementias on people living with the disease and their caregivers. During the Summit, attendees will hear updates on the coordinated national response to Alzheimer's disease and related dementias, including panel presentations on care, services, and supports, as well as research, innovation, and prevention. During the fourth and final Advisory Council meeting of 2026, the Advisory Council will hear from a panel organized by the clinical care subcommittee, receive budget updates from the National Institutes of Health, and hear a presentation on innovation in Alzheimer's disease interventions using focused ultrasound technology.

DATES: The events will be held on Monday, October 19, 2026. The Summit will take place from 9:30 a.m. to noon ET and the Advisory Council meeting will be held from 1:00 to 5:00 p.m. ET.

ADDRESSES: The Summit will be held in person, and the Advisory Council meeting will be a hybrid of in-person and virtual. Both events will be held in the Great Hall of the Hubert H. Humphrey Building, 200 Independence Avenue SW, Washington, DC 20201. They will also stream live at www.hhs.gov/live.

FOR FURTHER INFORMATION CONTACT:

Maria-Theresa Okafor, 771–223–7102, maria-theresa.okafor@hhs.gov.

SUPPLEMENTARY INFORMATION: Notice of these meetings is given under the Federal Advisory Committee Act (5 U.S.C. App. 2, section 10(a)(1) and

(a)(2)). Topics of the Meeting: Alzheimer's disease and related dementias, department initiatives, clinical care, and innovation.

Procedure and Agenda: The events will be webcast at www.hhs.gov/live and video recordings will be added to the National Alzheimer's Project Act website¹ when available after the meeting. These events are open to the public.

Public Attendance and Registration: To register for the Summit, the Advisory Council meeting, or both, please complete the registration form by Monday, October 12: <https://forms.cloud.microsoft/g/QLYF2dvykW>. In-person seating for members of the public is limited and will be available on a first-come, first-served basis. Submitting the registration form does not reserve or guarantee a seat. The names of expected in-person attendees will be provided to HHS security. Any interested member of the public who is a non-U.S. citizen should include this information on the registration form to ensure that the appropriate security procedure to gain entry to the building is carried out. Although the meeting is open to the public, procedures governing security and entrance to Federal buildings may change without notice. If you wish to make a public comment, you must indicate on your registration form. Please note that individuals entering HHS owned, leased, or operated facilities must present a REAL ID compliant credential or another federally approved form of identification. Below is the list of acceptable forms of ID.

- State-issued Enhanced Driver's License
- U.S. passport²
- U.S. passport card³
- DHS trusted traveler cards (Global Entry, NEXUS, SENTRI, FAST)
- U.S. Department of Defense ID, including IDs issued to dependents
- Permanent resident card
- Border crossing card
- An acceptable photo ID issued by a federally recognized⁴ Tribal Nation/Indian Tribe, including Enhanced Tribal Cards (ETCs)
- HSPD–12 PIV card
- Foreign government-issued passport

¹ <https://aspe.hhs.gov/collaborations-committees-advisory-groups/napa>.

² <https://travel.state.gov/content/travel/en/passports.html>.

³ <https://travel.state.gov/content/travel/en/passports/need-passport/card.html>.

⁴ <https://www.federalregister.gov/documents/2021/01/29/2021-01606/indian-entities-recognized-by-and-eligible-to-receive-services-from-the-united-states-bureau-of>.

- Canadian provincial driver's license or Indian and Northern Affairs Canada card
- Transportation worker identification credential
- U.S. Citizenship and Immigration Services Employment Authorization Card (I–766)
- U.S. Merchant Mariner Credential
- Veteran Health Identification Card (VHIC)

Comments: Time will be allocated on the agenda to hear public comments from 3:30 p.m. to 3:55 p.m. Oral comments will be limited to two (2) minutes per individual. Individuals who wish to provide an oral public comment must register using the registration form no later than Monday, October 12: <https://forms.cloud.microsoft/g/QLYF2dvykW>.

Registered commenters participating virtually will receive a meeting link and dial-in number and may use either option to join the meeting. Individuals may also request that NAPA staff read their comments during the public comment session. To make this request, please select the applicable response on the registration form and email the comment to napa@hhs.gov with the subject line “October 19 Public Comments Reading Request.” Comments to be read by NAPA staff must be received by Monday, October 12. **Note:** There may be a 30–45 second delay in the livestream video presentation of the meeting. For this reason, if you have pre-registered to submit a public comment, it is important to connect to the meeting by 2:55 p.m., to ensure that you do not miss your name and allotted time when called. If you miss your name and allotted time to speak, you may not be able to make your public comment. All participant audio lines will be muted for the duration of the meeting and only unmuted by the Host at the time of the participant's public comment. Should you have questions during the meeting, email napa@hhs.gov and someone will respond to your message as quickly as possible. To ensure accuracy, please submit a written copy of oral comments for the record by emailing napa@hhs.gov by Wednesday, October 21, 2026. Please attach the comments as a Microsoft Word (.docx) file so they can be compiled for publication. You may also attach a PDF copy for reference, but a Word version is required. These comments will be shared on the website and reflected in the meeting summary.

• In lieu of oral comments, formal written comments may be submitted for the record by emailing them to napa@hhs.gov or mailing them to Maria-

Theresa Okafor, Ph.D., MCG, Designated Federal Officer, OASPE, 200 Independence Avenue SW, Room 438F.7, Washington, DC 20201 by Wednesday, October 21, 2026. Those submitting written comments should identify themselves and any relevant organizational affiliations.

Authority: 42 U.S.C. 11225; Section 2(e)(3) of the National Alzheimer's Project Act. The panel is governed by provisions of Public Law 92-463, as amended (5 U.S.C. Appendix 2), which sets forth standards for the formation and use of advisory committees.

Cynthia L. Goss,

Deputy Assistant Secretary for Planning and Evaluation (Health Policy), Performing the Delegable Duties of the Assistant Secretary for Planning and Evaluation.

[FR Doc. 2026-20385 Filed 10-2-26; 8:45 am]

BILLING CODE P

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health

Center for Scientific Review; Notice of Closed Meetings

Pursuant to section 1009 of the Federal Advisory Committee Act, as amended, notice is hereby given of the following meetings.

The meetings will be closed to the public in accordance with the provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5 U.S.C., as amended. The grant applications and the discussions could disclose confidential trade secrets or commercial property such as patentable material, and personal information concerning individuals associated with the grant applications, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy.

Name of Committee: Center for Scientific Review Special Emphasis Panel; Training and Career Development in Basic and Integrative Biological Sciences.

Date: October 28–29, 2026.

Time: 10:00 a.m. to 6:00 p.m.

Agenda: To review and evaluate grant applications.

Address: National Institutes of Health, Rockledge II, 6701 Rockledge Drive, Bethesda, MD 20892.

Meeting Format: Virtual Meeting.

Contact Person: Priya Srinivasan, Ph.D., Scientific Review Officer, Center for Scientific Review, National Institutes of Health, 6701 Rockledge Drive, Bethesda, MD 20892, (240) 276-6459, priya.srinivasan@nih.gov.

Name of Committee: Center for Scientific Review Special Emphasis Panel; Neuropathophysiology of Addictive Substances.

Date: October 28–29, 2026.

Time: 10:00 a.m. to 9:00 p.m.

Agenda: To review and evaluate grant applications.

Address: National Institutes of Health, Rockledge II, 6701 Rockledge Drive, Bethesda, MD 20892.

Meeting Format: Virtual Meeting.

Contact Person: Eileen Marie Moore, Ph.D., Scientific Review Officer, Center for Scientific Review, National Institutes of Health, 6701 Rockledge Drive, Bethesda, MD 20892, (301) 594-8928, eileen.moore@nih.gov.

Name of Committee: Center for Scientific Review Special Emphasis Panel; Training: Institutional Research Grant.

Date: October 28, 2026.

Time: 10:00 a.m. to 6:00 p.m.

Agenda: To review and evaluate grant applications.

Address: National Institutes of Health, Rockledge II, 6701 Rockledge Drive, Bethesda, MD 20892.

Meeting Format: Virtual Meeting.

Contact Person: Srihari Seshadri, Ph.D., Scientific Review Officer, Center for Scientific Review, National Institutes of Health, 6701 Rockledge Dr., Bethesda, MD 20817, (301) 594-4738, srihari.seshadri@nih.gov.

Name of Committee: Oncology 1—Basic Translational Integrated Review Group; Biochemical and Cellular Oncogenesis Study Section.

Date: October 28–29, 2026.

Time: 10:00 a.m. to 6:00 p.m.

Agenda: To review and evaluate grant applications.

Address: National Institutes of Health, Rockledge II, 6701 Rockledge Drive, Bethesda, MD 20892.

Meeting Format: Virtual Meeting.

Contact Person: Jian Cao, M.D., Scientific Review Officer, Center for Scientific Review, National Institutes of Health, 6701 Rockledge Drive, Bethesda, MD 20892, (301) 827-5902, caojn@csr.nih.gov.

Name of Committee: Center for Scientific Review Special Emphasis Panel; Training: Career Development.

Date: October 28–29, 2026.

Time: 11:00 a.m. to 6:00 p.m.

Agenda: To review and evaluate grant applications.

Address: National Institutes of Health, Rockledge II, 6701 Rockledge Drive, Bethesda, MD 20892.

Meeting Format: Virtual Meeting.

Contact Person: Delia Tang, M.D., Scientific Review Officer, Center for Scientific Review, National Institute of Health, 6701 Rockledge Drive Bethesda, MD 20892, (240) 276-6456, tangd@mail.nih.gov.

Name of Committee: Center for Scientific Review Special Emphasis Panel; Biology Of Complex Brain Disorders.

Date: October 29–30, 2026.

Time: 9:00 a.m. to 6:00 p.m.

Agenda: To review and evaluate grant applications.

Address: National Institutes of Health, Rockledge II, 6701 Rockledge Drive, Bethesda, MD 20892.

Meeting Format: Virtual Meeting.

Contact Person: Adem Can, Ph.D., Scientific Review Officer, Center for Scientific Review, National Institutes of Health, 6701 Rockledge Drive, Room 4190, MSC 7850, Bethesda, MD 20892, (301) 451-7863, cana2@csr.nih.gov.

Name of Committee: Center for Scientific Review Special Emphasis Panel; Collaborative International Research in Health Promotion and Interventions.

Date: October 29, 2026.

Time: 9:00 a.m. to 6:00 p.m.

Agenda: To review and evaluate grant applications.

Address: National Institutes of Health, Rockledge II, 6701 Rockledge Drive, Bethesda, MD 20892.

Meeting Format: Virtual Meeting.

Contact Person: Xinli Nan, M.D., Ph.D., Scientific Review Officer, Center for Scientific Review, National Institutes of Health, 6701 Rockledge Drive, Bethesda, MD 20892, (301) 594-7784, Xinli.Nan@nih.gov.

Name of Committee: Center for Scientific Review Special Emphasis Panel; Health and Medical Technologies for Clinical Decision Making.

Date: October 29, 2026.

Time: 9:00 a.m. to 7:00 p.m.

Agenda: To review and evaluate grant applications.

Address: National Institutes of Health, Rockledge II, 6701 Rockledge Drive, Bethesda, MD 20892.

Meeting Format: Virtual Meeting.

Contact Person: Siddhartha Shankar Roy, Ph.D., Scientific Review Officer, Center for Scientific Review, National Institutes of Health, 6701 Rockledge Drive, Bethesda, MD 20892, (706) 373-3901, royss@csr.nih.gov.

Name of Committee: Center for Scientific Review Special Emphasis Panel; RFA-DA-26-056: Accelerating the Pace of Substance Use Research Using Existing Data (R21).

Date: October 29, 2026.

Time: 9:00 a.m. to 6:00 p.m.

Agenda: To review and evaluate grant applications.

Address: National Institutes of Health, Rockledge II, 6701 Rockledge Drive, Bethesda, MD 20892.

Meeting Format: Virtual Meeting.

Contact Person: Magnus A. Azuine, Ph.D., Scientific Review Officer, Center for Scientific Review, National Institutes of Health, 6701 Rockledge Drive, Bethesda, MD 20892, (301) 435-7579, magnus.azuine@nih.gov.

Name of Committee: Center for Scientific Review Special Emphasis Panel; Skeletal Connective Tissue Biology (SCTB).

Date: October 29–30, 2026.

Time: 9:00 a.m. to 5:00 p.m.

Agenda: To review and evaluate grant applications.

Address: National Institutes of Health, Rockledge II, 6701 Rockledge Drive, Bethesda, MD 20892.

Meeting Format: Virtual Meeting.

Contact Person: Kan Ma, Ph.D., Scientific Review Officer, Center for Scientific Review, National Institutes of Health, 6701 Rockledge Drive, Bethesda, MD 20892, (301) 451-4838, mak2@mail.nih.gov.

Name of Committee: Aging and Neurodegeneration Integrated Review Group;